Sulfonylurea

The way that type 2 diabetics respond to initial treatment could predict the long term effectiveness of their treatment regimen… There are a variety of treatment options for type 2 diabetics, with no clear reason why some drugs work better than others in some individuals. That is why diabetes treatment …

GLP-1 agonists have additional benefits for type 2 diabetes besides lower blood glucose… Over 1.4 billion adults were overweight in 2008, and of the 1.4 billion people, 500 million were obese. Obesity is defined as a body mass index >30 g/m2. Also, obesity increases the chance of being diagnosed with …

In the study, sulfonylureas correlated with a significant increase in levels of free fatty acids….

Drug shows a significant reduction in HbA1c in patients with type 2 diabetes… A new investigational drug is underway to help with reduction of HbA1c, weight, and improve glycemic control in type 2 diabetes patients. ITCA 650 is an injection-free GLP-1 receptor agonist that provides continuous subcutaneous exenatide for 12 …

Sulfonylureas not associated with increased cardiovascular mortality, myocardial infarction and stroke in a meta-analysis of 47 randomized clinical trials… Sulfonylureas are relatively inexpensive and are important therapeutic agents in type 2 diabetes management. However, they are not widely used due to safety concerns regarding hypoglycemia and weight gain. Furthermore, it …

GLP-1 analog also showed reduction in weight and incidence of hypoglycemia… Dulaglutide (Trulicity) is a glucagon-like peptide analog that is used once weekly to improve blood glucose level. During the open-label, multinational, parallel arm study, researchers compared the safety and efficacy of dulaglutide 0.75mg and 1.5mg to insulin glargine in …

Program helps aid primary care physicians in the management of patients with diabetes using individualized therapy…. A meta-analysis showed that the most efficacious strategies to improve glucose control were: case management, health care team changes, patient education, and facilitated transmission of patient data to clinicians. Using those 4 key strategies …

Device implantation could be the future in T2DM and weight loss… Weight gain is often a side effect of several different oral antidiabetic drugs (OADs), such as sulfonylureas and thiazolidinedion, along with insulin. Lifestyle modification and weight loss is always recommended in T2DM, but we all know it takes great …

Older veterans with T2DM and dementia may need to decrease intensity of diabetes medications… One study predicts that the prevalence of diabetes among adults aged ≥65 years is projected to increase dramatically by 2050. Other studies have observed that dementia affects up to 16% of diabetic patients aged ≥65 years …

Addition of dapagliflozin may benefit patients whose blood glucose is uncontrolled with both metformin and sulfonylurea… Dapagliflozin is a selective and reversible sodium-glucose co-transporter 2 (SGLT2) inhibitor, which lowers plasma glucose level by increasing urinary excretion of glucose. Addition of dapagliflozin may benefit patients whose blood glucose is uncontrolled with …